Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BioNTech SE - American Depositary Shares (NQ:BNTX)

109.83 -1.77 (-1.59%)
Streaming Delayed Price Updated: 2:38 PM EDT, Apr 22, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about BioNTech SE - American Depositary Shares

< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
72 73 Next >
News headline image
BioNTech to Present Clinical Data Updates for Next-Generation Immunotherapy Candidates at the ASCO Annual Meeting 2024
From BioNTech SE
Via GlobeNewswire
News headline image
3 Blue-Chip Stocks Set to Triple Soon ↗
Blue-chip stocks are great additions to a portfolio. If you're looking for consistent returns, check out these blue-chip stocks to buy. 
Via InvestorPlace
News headline image
European Patent Office Sides with Moderna In COVID-19 Vaccine Patent Dispute With Pfizer/BioNTech ↗
Moderna wins a crucial legal battle at the European Patent Office against Pfizer and BioNTech over Covid-19 vaccine patents. 
Via Benzinga
Topics Intellectual Property
News headline image
BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2024
From BioNTech SE
Via GlobeNewswire
News headline image
Cracking The Code: Understanding Analyst Reviews For BioNTech ↗
 
Via Benzinga
News headline image
Elon Musk Breaks Ranks With GOP By Praising Genetic Engineering Tech That Helped Fight COVID-19: 'Digital Medicine With Incredible Potential' ↗
Elon Musk has come off as a flagbearer of the mRNA technology, which is seen holding out a lot of promise by scientists. 
Via Benzinga
News headline image
BioNTech Se (BNTX) Q1 2024 Earnings Call Transcript ↗
BNTX earnings call for the period ending March 31, 2024. 
Via The Motley Fool
Topics Earnings
News headline image
BNTX Stock Earnings: BioNTech Misses EPS, Misses Revenue for Q1 2024 ↗
BNTX stock results show that BioNTech missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
What's Going With BioNTech Stock On Monday? ↗
BioNTech reports Q1 loss, missing revenue expectations. Despite challenges, BioNTech aims for significant growth, fueled by innovative R&D and strong cash reserves. 
Via Benzinga
News headline image
BioNTech Slides After Reporting Losses As Covid Vaccine Sales Take A Hit ↗
BioNTech missed the Street's sales views and reported wider-than-expected losses. 
Via Investor's Business Daily
News headline image
Assessing BioNTech: Insights From 11 Financial Analysts ↗
 
Via Benzinga
News headline image
Cracking The Code: Understanding Analyst Reviews For BioNTech ↗
 
Via Benzinga
News headline image
BioNTech Reports Downbeat Earnings, Joins Medical Properties Trust And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Wall Street Looks To Extend Rally Amid Caution Over Fed Speeches, More Earnings: Why This Analyst Thinks Bull Market Is Still 'Quite Young' ↗
U.S. stocks are likely to extend their gains as major index futures are modestly higher on Monday. Strong earnings reports continue to support the market, with S&P 500 earnings expected to grow by 5%... 
Via Benzinga
Topics Economy
News headline image
BioNTech Announces First Quarter 2024 Financial Results and Corporate Update
From BioNTech SE
Via GlobeNewswire
News headline image
Will Earnings Cheer Continue This Week? All Eyes On Disney, Palantir, Robinhood While Reddit Gears Up For Debut Quarterly Report ↗
According to FactSet, a financial data analytics firm, 80% of S&P 500 companies have reported earnings so far. 
Via Benzinga
Topics Stocks
News headline image
GSK Sees Strong Demand For Vaccines and Asthma Drugs, Raises Annual Outlook ↗
Discover GSK's first-quarter performance, boasting a 10% Y/Y sales surge to £7.4 billion. Notable growth in Vaccines and Specialty Medicines, propelled by strong demand for Arexvy and Shingrix.... 
Via Benzinga
News headline image
COVID-19 Patent Dispute Sorted: Acuitas Therapeutics and CureVac Reach Settlement In Patent Battle ↗
Acuitas Therapeutics settles lawsuit with CureVac over COVID-19 vaccine patents. Legal disputes unfold among biotech giants Pfizer, BioNTech, and CureVac, as GSK joins the fray, alleging patent... 
Via Benzinga
Topics Intellectual Property Lawsuit
News headline image
What's Going On With Pfizer Stock On Thursday? ↗
GSK initiates legal proceedings against Pfizer and BioNTech over alleged COVID-19 vaccine patent infringement, intensifying high-stakes legal battles in the U.S. 
Via Benzinga
Topics Intellectual Property
News headline image
Moderna Faces Pfizer, BioNTech in London Patent Battle over Covid-19 Vaccines In Legal Showdown ↗
Moderna challenges Pfizer and BioNTech in a London patent trial over mRNA vaccine patents. The outcome may reshape the pharmaceutical landscape, impacting future innovations and revenue streams. 
Via Benzinga
Topics Intellectual Property
News headline image
BioNTech to Report First Quarter 2024 Financial Results and Corporate Update on May 6, 2024
From BioNTech SE
Via GlobeNewswire
News headline image
Bill Gates Called For A 'Universal Flu Vaccine,' Now The CDC Director Says The Organization Is 'Activated' After Issuing Bird Flu Alert ↗
 
Via Benzinga
News headline image
Election Year Encore: Can 2020’s Top 7 Stock Winners Repeat Their Performance in 2024? ↗
These seven companies were the top 2020 stocks. After their glory years have faded, they are looking to turn their fortunes around. 
Via InvestorPlace
News headline image
Three-year Phase 1 Follow-Up Data for mRNA-based Individualized Immunotherapy Candidate Show Persistence of Immune Response and Delayed Tumor Recurrence in Some Patients with Resected Pancreatic Cancer
From BioNTech SE
Via GlobeNewswire
News headline image
CureVac, GS Partner Release Data On Influenza Vaccine Study ↗
CureVac reveals Phase 2 interim data for its seasonal influenza vaccine in collaboration with GSK. Results show broad antigen coverage with acceptable safety. Positive findings against influenza A... 
Via Benzinga
News headline image
The 3 Best Bargain Stocks to Buy in Q2 2024 ↗
For those who don’t want to chase what everyone else is acquiring, these are intriguing ideas for best bargain stocks to buy. 
Via InvestorPlace
News headline image
3 Biotech Stocks to Buy for the Next Bull Run: March 2024 ↗
These biotech stocks to buy are well positioned for growth, and will generate solid returns for investors in the next bull run. 
Via InvestorPlace
News headline image
BioNTech Se (BNTX) Q4 2023 Earnings Call Transcript ↗
BNTX earnings call for the period ending December 31, 2023. 
Via The Motley Fool
Topics Earnings
News headline image
Why Lifecore Biomedical Shares Are Trading Lower By Around 32%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗
Shares of Lifecore Biomedical, Inc. (NASDAQ: LFCR) fell sharply during Wednesday’s session after the company announced it concluded its strategic evaluation process, announced management succession and... 
Via Benzinga
News headline image
BioNTech Touts Its Oncology Shift After Reporting Disappointing Fourth Quarter Financials ↗
BioNTech SE (NASDAQ: BNTX) is way past its glorious Covid-19 days, when it thrived with Pfizer Inc (NYSE: PFE) for saving the world from the pandemic with their jointly developed vaccine. 
Via Benzinga
< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
72 73 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.